AstraZeneca PLC (AZNCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AstraZeneca PLC (AZNCF) trades at $189.90 with AI Score 60/100 (Grade B+). AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Market cap: $294.40B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for AZNCF: AZNCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AZNCF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AZNCF: 2/4 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →AstraZeneca PLC (AZNCF) Healthcare & Pipeline Overview
AstraZeneca PLC is a global biopharmaceutical leader specializing in prescription medicines across oncology, cardiovascular, renal & metabolism, and respiratory & immunology. With a strong focus on innovation and strategic collaborations, AstraZeneca serves primary and specialty care physicians worldwide, maintaining a significant presence in key therapeutic areas.
What Is the Investment Thesis for AZNCF?
AstraZeneca PLC presents a compelling investment case driven by its robust product portfolio and strategic focus on key therapeutic areas. With a market capitalization of $294.40B and a profit margin of 17.4%, the company demonstrates financial stability. Growth catalysts include ongoing collaborations and the development of novel therapies, particularly in oncology and rare diseases. The company's dividend yield of 1.64% provides a steady return for investors. However, potential risks include regulatory hurdles and competition from other pharmaceutical giants. The company's P/E ratio of 26.7 reflects investor expectations of future growth.
Based on FMP financials and quantitative analysis
AZNCF Key Highlights
- Market Cap of $294.40B indicates a strong market presence and investor confidence.
- Profit Margin of 17.4% demonstrates efficient operations and profitability.
- Gross Margin of 78.2% reflects strong pricing power and cost management.
- Dividend Yield of 1.64% provides a steady income stream for investors.
- Beta of 0.19 suggests lower volatility compared to the overall market.
Who Are AZNCF's Competitors?
AZNCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHGCF Chugai Pharmaceutical Co., Ltd. | $46.51 | +0.93% | $76.54B | 55 |
| CHGCY Chugai Pharmaceutical Co., Ltd. | $23.26 | -0.47% | $76.56B | 55 |
| FSNUY Fresenius SE & Co. KGaA | $12.50 | +3.91% | $112.65B | 43 |
| NONOF Novo Nordisk A/S | $48.95 | -0.26% | $217.48B | 52 |
| NVSEF Novartis AG | $156.65 | +2.13% | $298.90B | 55 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AZNCF's Key Strengths?
- Strong product portfolio in key therapeutic areas.
- Robust research and development pipeline.
- Global presence and distribution network.
- Strategic collaborations and partnerships.
What Are AZNCF's Weaknesses?
- Reliance on patent protection for key drugs.
- Exposure to generic competition.
- Regulatory risks and challenges.
- High research and development costs.
What Could Drive AZNCF Stock Higher?
- Clinical trial results for key drug candidates in oncology and other therapeutic areas.
- Regulatory approvals for new drugs and indications.
- Strategic collaborations and partnerships to expand the product pipeline.
- Expansion into emerging markets to drive revenue growth.
- Continued focus on research and development to innovate new therapies.
What Are the Key Risks for AZNCF?
- Patent expirations and loss of exclusivity for key drugs.
- Increasing competition from generic drug manufacturers.
- Pricing pressures and healthcare reforms.
- Regulatory risks and challenges.
- High research and development costs.
What Are the Growth Opportunities for AZNCF?
- Expansion in Oncology: AstraZeneca has a significant opportunity to expand its oncology portfolio, which includes key drugs like Lynparza and Tagrisso. The global oncology market is projected to reach $286.6 billion by 2030, driven by increasing cancer prevalence and advancements in targeted therapies. AstraZeneca's ongoing research and development efforts, coupled with strategic acquisitions, position it to capture a larger share of this growing market. The company's focus on precision medicine and immuno-oncology offers a competitive edge.
- Cardiovascular, Renal & Metabolism (CVRM) Growth: AstraZeneca's CVRM franchise, featuring drugs like Farxiga, presents a substantial growth opportunity. The global market for cardiovascular drugs is expected to reach $165 billion by 2028, driven by the rising incidence of heart disease and diabetes. AstraZeneca's innovative therapies and focus on preventative care position it to capitalize on this trend. The company's commitment to addressing unmet needs in CVRM through novel drug development supports long-term growth.
- Respiratory & Immunology Advancements: AstraZeneca's respiratory and immunology portfolio, including products like Symbicort and Fasenra, offers growth potential. The global respiratory disease market is projected to reach $47.7 billion by 2027, driven by increasing air pollution and the prevalence of asthma and COPD. AstraZeneca's focus on developing inhaled therapies and biologics for respiratory diseases provides a competitive advantage. The company's expansion into biologics for autoimmune diseases further enhances its growth prospects.
- Rare Diseases Portfolio Expansion: AstraZeneca's acquisition of Alexion Pharmaceuticals has significantly expanded its presence in the rare diseases market. The global rare diseases market is expected to reach $258.74 billion by 2030, driven by increased awareness and advancements in genetic testing. AstraZeneca's portfolio, including Soliris and Ultomiris, positions it to address unmet needs in this growing market. The company's focus on developing innovative therapies for rare genetic disorders supports long-term growth.
- Strategic Collaborations and Partnerships: AstraZeneca's collaborations with companies like Regeneron, Neurimmune, and Ionis Pharmaceuticals provide access to innovative technologies and drug candidates. These partnerships enable AstraZeneca to expand its pipeline and address unmet needs in various therapeutic areas. The company's collaborative approach to drug development accelerates innovation and enhances its competitive position. Ongoing collaborations are expected to contribute to long-term growth and diversification of its product portfolio.
What Opportunities Does AZNCF Have?
- Expansion into emerging markets.
- Development of novel therapies for unmet needs.
- Strategic acquisitions and partnerships.
- Growth in personalized medicine and targeted therapies.
What Threats Does AZNCF Face?
- Increasing competition from generic drug manufacturers.
- Pricing pressures and healthcare reforms.
- Patent expirations and loss of exclusivity.
- Adverse regulatory decisions.
What Are AZNCF's Competitive Advantages?
- Patent protection for key drugs provides exclusivity and pricing power.
- Strong brand reputation and established relationships with healthcare providers.
- Extensive research and development capabilities drive innovation.
- Global distribution network ensures broad market access.
- Specialized expertise in key therapeutic areas creates a competitive advantage.
What Does AZNCF Do?
AstraZeneca PLC, established in 1992 and headquartered in Cambridge, UK, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing prescription medicines. Formed through the merger of Astra AB and Zeneca Group PLC in 1999, AstraZeneca has evolved into a major player in the pharmaceutical industry. The company's diverse portfolio includes well-known products such as Calquence, Enhertu, and Lynparza in oncology; Brilinta and Farxiga in cardiovascular, renal, and metabolism; and Symbicort and Fasenra in respiratory and immunology. AstraZeneca also addresses rare diseases with products like Soliris and Ultomiris. The company operates globally, serving primary care and specialty care physicians through distributors and local representative offices across Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca's commitment to innovation is underscored by its collaborations with companies like Regeneron Pharmaceuticals, Neurimmune AG, Ionis Pharmaceuticals, Proteros Biostructures GmbH, and Sierra Oncology, Inc., focusing on areas such as obesity, neurological disorders, and cancer treatments.
What Products and Services Does AZNCF Offer?
- Discovers and develops prescription medicines.
- Manufactures pharmaceutical products.
- Commercializes prescription medicines globally.
- Focuses on therapeutic areas including oncology, cardiovascular, renal & metabolism, and respiratory & immunology.
- Addresses rare diseases with specialized treatments.
- Develops vaccines for infectious diseases like COVID-19 and influenza.
- Engages in research and development collaborations with other companies.
How Does AZNCF Make Money?
- Develops and patents new pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Obtains regulatory approvals from agencies like the FDA and EMA.
- Manufactures and distributes drugs through distributors and local offices.
- Markets and sells prescription medicines to healthcare providers and patients.
What Industry Does AZNCF Operate In?
AstraZeneca operates in the highly competitive global pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. AstraZeneca competes with major pharmaceutical companies, including CHGCF (Chugai Pharmaceutical Co.), CHGCY (Chugai Pharmaceutical Co.), FSNUY (Fresenius SE & Co), NONOF (Novo Nordisk), and NVSEF (Novartis). The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products.
Who Are AZNCF's Key Customers?
- Primary care physicians
- Specialty care physicians
- Hospitals and clinics
- Patients with various medical conditions
- Government healthcare organizations
FY2026 estForward Outlook
Wall Street analysts project AstraZeneca PLC revenue of about $62.32B for fiscal 2026, with EPS near $10.29. The estimate reflects 24 contributing analysts.
F-Score 7/9Financial Health
AstraZeneca PLC's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.74 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 22%Key Financial Metrics
Return on equity for AstraZeneca PLC stands at 22.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.2%, showing how much profit it generates from its asset base. AZNCF trades at a trailing price-to-earnings ratio of 26.70, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.91 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.7%, the inverse of the P/E and a quick read on earnings relative to price.
AstraZeneca PLC (AZNCF) Valuation Context
Valued at $294.40B, AZNCF is classified as a mega-cap stock. Relative to its peer group, AZNCF's quantitative score of 60/100 is roughly in line with the peer average of 52/100.
AZNCF Revenue & Earnings Trend
In Q4 2025, AZNCF generated $15.50B in top-line revenue, marking a sequential increase of 2.1%. The company recorded net income of $2.33B, with diluted EPS of $1.49. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mega-cap Healthcare company. Across the four most recent quarters, AZNCF averaged $1.64 in diluted EPS.
Company Profile
AstraZeneca PLC operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Cambridge, GB. The company is led by CEO Pascal Claude Roland Soriot. AZNCF has traded publicly since 2009.
AZNCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in AstraZeneca's future growth, signaling potential positive developments ahead.
- Community sentiment has shifted positively, with many discussions highlighting the company's innovative pipeline in oncology and vaccines.
- Analysts are increasingly optimistic about AstraZeneca's strategic partnerships, which could enhance their market position and revenue streams.
- The company has maintained strong operational performance, reflecting resilience in a competitive pharmaceutical landscape.
Bear Case
- Concerns about regulatory hurdles for new drug approvals have been prevalent in community discussions, creating uncertainty around future growth.
- Recent market sentiment shows skepticism regarding the sustainability of AstraZeneca's recent revenue boosts, leading to cautious investor attitudes.
- Some analysts highlight increasing competition in key therapeutic areas, which could pressure AstraZeneca's market share and profitability.
- Negative news around potential side effects of new treatments has sparked debates, causing a bearish outlook among certain community members.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $15.50B | $2.33B | $1.49 |
| Q3 2025 | $15.19B | $2.53B | $1.62 |
| Q2 2025 | $14.46B | $2.45B | $1.57 |
| Q1 2025 | $13.59B | $2.99B | $1.87 |
Based on FMP financials and quantitative analysis
AZNCF Latest News
No recent news available for AZNCF.
AZNCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AZNCF.
Price Targets
Wall Street price target analysis for AZNCF.
AZNCF MoonshotScore
What does this score mean?
The MoonshotScore rates AZNCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Pascal Claude Roland Soriot
Chief Executive Officer
Pascal Soriot has served as the Chief Executive Officer of AstraZeneca since October 2012. Prior to joining AstraZeneca, he held various leadership positions at Roche, including Chief Operating Officer of Roche's pharmaceuticals division. Soriot holds a Doctor of Veterinary Medicine degree from the École Nationale Vétérinaire d'Alfort and an MBA from HEC Paris. His extensive experience in the pharmaceutical industry spans over three decades, with a focus on strategic leadership and global operations.
Track Record: Under Pascal Soriot's leadership, AstraZeneca has undergone a significant transformation, focusing on innovation and strategic acquisitions. Key achievements include the successful integration of Alexion Pharmaceuticals, the development of blockbuster drugs like Tagrisso and Farxiga, and the expansion of the company's oncology pipeline. Soriot has also overseen the company's response to the COVID-19 pandemic, including the development and distribution of the AstraZeneca vaccine.
AZNCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AstraZeneca PLC (AZNCF) may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier typically involves higher risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Increased risk of fraud or manipulation.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC securities.
- AstraZeneca PLC is a well-established global pharmaceutical company.
- The company has a diverse portfolio of prescription medicines.
- AstraZeneca PLC is listed on the London Stock Exchange (LSE: AZN).
- The company has a strong reputation in the pharmaceutical industry.
- AstraZeneca PLC is committed to research and development.
AZNCF Healthcare Stock FAQ
What does AstraZeneca PLC do?
AstraZeneca PLC is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. The company focuses on key therapeutic areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca's products are sold worldwide to primary care and specialty care physicians, hospitals, and government healthcare organizations. The company also engages in research and development collaborations to expand its product pipeline and address unmet medical needs.
What do analysts say about AZNCF stock?
Analyst consensus for AZNCF stock is generally positive, reflecting the company's strong product portfolio and growth prospects. Key valuation metrics, such as the P/E ratio of 26.7, suggest that investors expect future earnings growth. Considerations include the company's ongoing research and development efforts, strategic collaborations, and expansion into emerging markets. However, analysts also note potential risks, such as patent expirations and regulatory challenges. No buy/sell recommendations are made in this research report.
What are the main risks for AZNCF?
The main risks for AZNCF include patent expirations and loss of exclusivity for key drugs, increasing competition from generic drug manufacturers, pricing pressures and healthcare reforms, regulatory risks and challenges, and high research and development costs. These factors could negatively impact the company's revenue, profitability, and market share. Investors should carefully consider these risks before investing in AZNCF stock. The OTC market also presents additional risks.
What are the key factors to evaluate for AZNCF?
AstraZeneca PLC (AZNCF) holds an AI score of 60/100 (moderate). P/E: 26.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does AZNCF data refresh on this page?
AZNCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AZNCF's recent stock price performance?
AstraZeneca PLC (AZNCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product portfolio in key therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AZNCF overvalued or undervalued right now?
AstraZeneca PLC (AZNCF) trades at 26.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AZNCF?
Before investing in AstraZeneca PLC (AZNCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide additional insights.